Patents by Inventor Kristopher Toy
Kristopher Toy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240130822Abstract: Systems and methods for managing surgical sponges. A dispenser assembly coupled to a main support includes an internal or first storage location to removably receive a carton of sponge sorters, and an external or second storage location to removably support a carton of surgical draping. At least one arm may be supported on the housing and movable between an undeployed position and a deployed position. The arm may include weighing means to measure a weight of the surgical sponge being disposed in a sponge sorter supported by the arm. The arm may be a cantilever and abeam load cell may be disposed within a channel of a beam. A processor may determine fluid weight based on measured weight and dry weight correlated with the surgical sponge being counted out as detected with a data reader. The processor may estimate blood loss to be displayed on a display.Type: ApplicationFiled: February 24, 2022Publication date: April 25, 2024Applicant: Stryker CorporationInventors: Brian James VanDerWoude, Caroline Weinberg, Fazel Yavari, Kristopher Kendall Biegler, Jonathon Emanuel Koenig, Alex Surasky-Ysasi, Tyler Toy, Rachel Wallace, Colin Vincent Beney, Kenneth Lee Soliva
-
Publication number: 20220002428Abstract: The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.Type: ApplicationFiled: July 13, 2021Publication date: January 6, 2022Applicants: Pfizer Inc., Bristol-Myers Squibb CompanyInventors: Jing MIN, Yanli WU, Rory F. FINN, Barrett R. THIELE, Wei LIAO, Ronald P. GLADUE, Arvind RAJPAL, Timothy J. PARADIS, Peter BRAMS, Brigitte DEVAUX, Yi WU, Kristopher TOY, Heidi N. LEBLANC, Haichun HUANG
-
Publication number: 20190135932Abstract: The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.Type: ApplicationFiled: January 11, 2019Publication date: May 9, 2019Applicants: Pfizer Inc., Bristol-Myers Squibb CompanyInventors: Jing MIN, Yanli WU, Rory F. FINN, Barrett R. THIELE, Wei LIAO, Ronald P. GLADUE, Arvind RAJPAL, Timothy J. PARADIS, Peter BRAMS, Brigitte DEVAUX, Yi WU, Kristopher TOY, Heidi N. LEBLANC, Haichun HUANG
-
Patent number: 10196452Abstract: The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.Type: GrantFiled: November 8, 2017Date of Patent: February 5, 2019Assignees: Pfizer Inc., Bristol-Myers Squibb CompanyInventors: Jing Min, Yanli Wu, Rory F. Finn, Barrett R. Thiele, Wei Liao, Ronald P. Gladue, Arvind Rajpal, Timothy J. Paradis, Peter Brams, Brigitte Devaux, Yi Wu, Kristopher Toy, Heidi N. Leblanc, Haichun Huang
-
Publication number: 20180057600Abstract: The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.Type: ApplicationFiled: November 8, 2017Publication date: March 1, 2018Applicants: Pfizer Inc., Bristol-Myers Squibb CompanyInventors: Jing MIN, Yanli Wu, Rory F. Finn, Barrett R. Thiele, Wei Liao, Ronald P. Gladue, Arvind Rajpal, Timothy J. Paradis, Peter Brams, Brigitte Devaux, Yi Wu, Kristopher Toy, Heidi N. Leblanc, Haichun Huang
-
Patent number: 9840562Abstract: The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.Type: GrantFiled: April 22, 2015Date of Patent: December 12, 2017Assignees: Bristol-Myers Squibb Company, Pfizer Inc.Inventors: Jing Min, Yanli Wu, Rory F. Finn, Barrett R. Thiele, Wei Liao, Ronald P. Gladue, Arvind Rajpal, Timothy J. Paradis, Peter Brams, Brigitte Devaux, Yi Wu, Kristopher Toy, Heidi N. LeBlanc, Haichun Huang
-
Publication number: 20170058031Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.Type: ApplicationFiled: November 10, 2016Publication date: March 2, 2017Inventors: David John King, Alison WITTE, Heidi N. LEBLANC, Richard THEOLIS, Asna MASOOD, Mark YAMANAKA, Kyra D. ZENS, Sarah R. REED, Tim SPROUL, Chetana RAO-NAIK, David Passmore, Dawn M. TANAMACHI, Kristopher TOY
-
Patent number: 9499632Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.Type: GrantFiled: February 20, 2013Date of Patent: November 22, 2016Assignee: E.R. Squibb & Sons, L.L.C.Inventors: David John King, Alison Witte, Heidi N. Leblanc, Richard Theolis, Asna Masood, Mark Yamanaka, Kyra D. Zens, Sarah R. Reed, Tim Sproul, Chetana Rao-Naik, David Passmore, Dawn M. Tanamachi, Kristopher Toy
-
Publication number: 20150218279Abstract: The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.Type: ApplicationFiled: April 22, 2015Publication date: August 6, 2015Inventors: Jing Min, Yanli Wu, Rory F. Finn, Barrett R. Thiele, Wei Liao, Ronald P. Gladue, Arvind Rajpal, Timothy J. Paradis, Peter Brams, Brigitte Devaux, Yi Wu, Kristopher Toy, Heidi N. LeBlanc, Haichun Huang
-
Publication number: 20150203574Abstract: Antibodies and antigen-binding portions thereof that bind to human IL-6 are provided. Also provided are nucleic acids encoding such antibodies and antigen binding portions, methods of making such antibodies and antigen binding portions, compositions comprising such antibodies or antigen binding portions, and uses of such antibodies or antigen binding portions.Type: ApplicationFiled: August 29, 2014Publication date: July 23, 2015Applicants: BRISTOL-MYERS SQUIBB COMPANY, PFIZER INC.Inventors: Arvind Rajpal, Madhav Narasimha Devalaraja, Kristopher Toy, Lan Yang, Haichun Huang, Jun Zhang, Peter Brams, Brigitte Devaux, David B. Passmore
-
Patent number: 9028824Abstract: The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.Type: GrantFiled: May 17, 2012Date of Patent: May 12, 2015Assignees: Pfizer Inc., Bristol-Myers Squibb CompanyInventors: Jing Min, Yanli Wu, Rory F. Finn, Barrett R. Thiele, Wei Liao, Ronald P. Gladue, Arvind Rajpal, Timothy J. Paradis, Peter Brams, Brigitte Devaux, Yi Wu, Kristopher Toy, Heidi N. LeBlanc, Haichun Huang
-
Patent number: 8846037Abstract: Antibodies and antigen-binding portions thereof that bind to human IL-6 are provided. Also provided are nucleic acids encoding such antibodies and antigen binding portions, methods of making such antibodies and antigen binding portions, compositions comprising such antibodies or antigen binding portions, and uses of such antibodies or antigen binding portions.Type: GrantFiled: April 5, 2013Date of Patent: September 30, 2014Assignees: Pfizer Inc., Bristol-Myers Squibb CompanyInventors: Arvind Rajpal, Madhav Narasimha Devalaraja, Kristopher Toy, Lan Yang, Haichun Huang, Jun Zhang, Peter Brams, Brigitte Devaux, David B. Passmore
-
Publication number: 20140154268Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin ?5?1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-?5?1 antibodies or antigen binding portions thereof described herein.Type: ApplicationFiled: February 21, 2013Publication date: June 5, 2014Applicants: PFIZER INC., BRISTOL-MYERS SQUIBB COMPANYInventors: STEVEN LEE BENDER, GERALD FRIES CASPERSON, DANA DAN HU-LOWE, XIN JIANG, GANG LI, MICHAEL AIDAN NORTH, JIANYING WANG, GRANT WICKMAN, PETER BRAMS, HAICHUN HUANG, BRIGITTE DEVAUX, HAIBIN CHEN, DAWN M. TANAMACHI, KRISTOPHER TOY, LAN YANG, TIM W. SPROUL, MARK YAMANAKA
-
Publication number: 20130280266Abstract: Antibodies and antigen-binding portions thereof that bind to human IL-6 are provided. Also provided are nucleic acids encoding such antibodies and antigen binding portions, methods of making such antibodies and antigen binding portions, compositions comprising such antibodies or antigen binding portions, and uses of such antibodies or antigen binding portions.Type: ApplicationFiled: April 5, 2013Publication date: October 24, 2013Applicants: BRISTOL-MYERS SQUIBB COMPANY, PFIZER INC.Inventors: Arvind Rajpal, Madhav Narasimha Devalaraja, Kristopher Toy, Lan Yang, Haichun Huang, Jun Z. Zhang, Peter Brams, Brigitte Devaux, David B. Passmore
-
Publication number: 20130230530Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.Type: ApplicationFiled: February 20, 2013Publication date: September 5, 2013Applicant: Medarex, Inc.Inventors: David John King, Alison Witte, Heidi N. Leblanc, Richard Theolis, Asna Masood, Mark Yamanaka, Kyra D. Zens, Sarah R. Reed, Tim Sproul, Chetana Rao-Naik, David Passmore, Dawn M. Tanamachi, Kristopher Toy
-
Patent number: 8481683Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.Type: GrantFiled: November 30, 2007Date of Patent: July 9, 2013Assignee: Medarex, Inc.Inventors: David John King, Alison Witte, Heidi N. LeBlanc, Richard Theolis, Asna Masood, Mark Yamanaka, Kyra D. Zens, Sarah R. Reed, Tim Sproul, Chetana Rao-Naik, David Passmore, Dawn M. Tanamachi, Kristopher Toy
-
Patent number: 8436158Abstract: Antibodies and antigen-binding portions thereof that bind to human IL-6 are provided. Also provided are nucleic acids encoding such antibodies and antigen binding portions, methods of making such antibodies and antigen binding portions, compositions comprising such antibodies or antigen binding portions, and uses of such antibodies or antigen binding portions.Type: GrantFiled: April 24, 2012Date of Patent: May 7, 2013Assignees: Pfizer Inc., Bristol-Myers Squibb CompanyInventors: Arvind Rajpal, Madhav Narasimha Devalaraja, Kristopher Toy, Lan Yang, Haichun Huang, Jun Zhang, Peter Brams, Brigitte Devaux, David B. Passmore
-
Patent number: 8425904Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of internalizing into mesothelin-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. The invention further provides anti-mesothelin antibodies that can inhibit the binding of mesothelin to the ovarian cancer antigen CA125. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided.Type: GrantFiled: August 16, 2012Date of Patent: April 23, 2013Assignee: Bristol-Myers Squibb CompanyInventors: Jonathan A. Terrett, Sarah L. Pogue, Kristopher Toy, Lan Yang, Chetana Rao-Naik, Bingliang Chen
-
Patent number: 8399623Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of internalizing into mesothelin-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. The invention further provides anti-mesothelin antibodies that can inhibit the binding of mesothelin to the ovarian cancer antigen CA125. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided.Type: GrantFiled: August 16, 2012Date of Patent: March 19, 2013Assignee: Bristol-Myers Squibb CompanyInventors: Jonathan A. Terrett, Sarah L. Pogue, Kristopher Toy, Lan Yang, Chetana Rao-Naik, Bingliang Chen
-
Patent number: 8399647Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin ?5?1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-?5?1 antibodies or antigen binding portions thereof described herein.Type: GrantFiled: September 20, 2011Date of Patent: March 19, 2013Assignees: Pfizer Inc., Bristol-Myers Squibb CompanyInventors: Steven L. Bender, Gerald F. Casperson, Dana D. Hu-Lowe, Xin Jiang, Gang Li, Michael A. North, Jianying Wang, Grant Wickman, Peter Brams, Haichun Huang, Brigitte Devaux, Haibin Chen, Dawn M. Tanamachi, Kristopher Toy, Lan Yang, Tim W. Sproul, Mark Yamanaka